What is Claimed is:

1. A pharmaceutical composition useful for the treatment or prophylaxis of viral infections comprising nevirapine and at least one antiviral active compound of formula (I)



I

wherein said Base is selected from the group consisting of: thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof.

2. The pharmaceutical composition according to claim 1 wherein the compound of formula (I) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

3. The pharmaceutical composition according to claim 1 wherein the compound of formula (I) is 2',3'-dideoxy-3'-fluoroguanosine (FLG) or a pharmaceutically acceptable salt or prodrug thereof.

4. The pharmaceutical composition according to claim 1 wherein the compound of formula (I) is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition according to claim 1 wherein nevirapine and the compound of formula (I) are present in a synergistic ratio.

6. The pharmaceutical composition according to claim 1 wherein nevirapine and the compound of formula (I) are present in a ratio between about 1:250 to about 250:1.

7. The pharmaceutical composition according to claim 6 wherein nevirapine and the compound of formula (I) are present in a ratio between about 1:50 to about 50:1.

8. The pharmaceutical composition according to claim 1 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

9. The pharmaceutical composition according to claim 1 further comprising at least one pharmaceutically acceptable carrier.

10. The pharmaceutical composition according to claim 1 further comprising a protease inhibitor.

11. The pharmaceutical composition according to claim 1 further comprising an entry inhibitor.

12. The pharmaceutical composition according to claim 10 further comprising an entry inhibitor.

13. The pharmaceutical composition according to claim 10 further comprising an integrase inhibitor.

14. The pharmaceutical composition according to claim 10 further comprising a further nucleoside reverse

transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

15. The pharmaceutical composition according to claim 11 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

16. The pharmaceutical composition according to claim 12 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

17. The pharmaceutical composition according to claim 13 further comprising a further nucleoside reverse transcriptase (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

18. The pharmaceutical composition according to claim 1 further comprising a maturation inhibitor or an antisense compound.

19. The pharmaceutical composition according to claim 1 further comprising an antiviral agent selected from the group consisting of: PA-457, KPC-2, HGTV-43, delavirdine, efavirenz, (+)- calanolide A and B, capravirine, GW-695634, MIV-150, MV026048, NV-05, R-278474, RS-1588, TMC-120/125, TMC-125, UC-781, and YM-215389.

20. A method for the prophylaxis or treatment of a viral infection in a patient comprising administering nevirapine in combination or alternation with at least one antiviral active compound of formula (I)



I

wherein Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof.

21. The method according to claim 20, wherein the compound of formula (I) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

22. The method according to claim 20, wherein the compound of formula (I) is 2',3'-dideoxy-3'-fluoroguanosine (FLG), or a pharmaceutically acceptable salt or prodrug thereof.

23. The method according to claim 20, wherein the compound of formula (I) is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine or a pharmaceutically acceptable salt thereof.

24. The method according to claim 20, wherein the viral infection is a human retroviral infection (HRV).

25. The method according to claim 24, wherein the human retroviral infection is a multiresistant human immunodeficiency virus (HIV) infection.

26. The method according to claim 24, wherein perinatal transmission of the human retroviral infection (HRV) from mother to baby is prevented.

27. The method according to claim 20, wherein nevirapine and the compound of formula (I) are administered to the patient in combination or alternation in a synergistic ratio.

28. The method according to claim 20, wherein nevirapine and the compound of formula (I) are administered to the patient in combination or alternation in a ratio between about 1:250 to about 250:1.

29. The method according to claim 28, wherein nevirapine and the at least one compound of formula (I) are administered to the patient in combination or alternation in a ratio between about 1:50 to about 50:1.

30. The method according to claim 20, further comprising administering in combination or alternation a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

31. The method according to claim 20 further comprising administering a protease inhibitor.

32. The method according to claim 20 further comprising administering an entry inhibitor.

33. The method according to claim 31 further comprising administering an entry inhibitor.

34. The method according to claim 31 further comprising administering an integrase inhibitor.

35. The method according claim 31 further comprising administering a further nucleoside reverse transcriptase

inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

36. The method according claim 32 further comprising administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

37. The method according claim 33 further comprising administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

38. The method according claim 34 further comprising administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

39. A kit of parts for the prophylaxis or treatment of a viral infection in a patient, comprising

(a) a first containment containing a pharmaceutical composition comprising nevirapine and at least one pharmaceutically acceptable carrier, and

(b) a second containment containing a pharmaceutical composition comprising an antiviral active compound of formula (I)



I

wherein Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable carrier.

40. The kit of parts according to claim 39, wherein the compound of formula (I) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

41. The kit of parts according to claim 39, wherein the compound of the formula (I) is 2',3'-dideoxy-3'-fluoroguanosine (FLG), or a pharmaceutically acceptable salt or prodrug thereof.

42. The kit of parts according to claim 39, wherein the compound of the formula (I) is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine or a pharmaceutically acceptable salt thereof.

43. The kit of parts according to claim 39 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

44. The kit of parts according to claim 39 further comprising a containment containing a pharmaceutical composition comprising a protease inhibitor.

45. The kit of parts according to claim 39 further comprising a containment containing a pharmaceutical composition comprising an entry inhibitor.

46. The kit of parts according to claim 44 further comprising a containment containing a pharmaceutical composition comprising an entry inhibitor.

47. The kit of parts according to claim 44 further comprising a containment containing a pharmaceutical composition comprising an integrase inhibitor.

48. The kit of parts according to claim 44 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

49. The kit of parts according to claim 45 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

50. The kit of parts according to claim 46 further comprising a containment containing a pharmaceutical composition comprising a further NRTI, or a pharmaceutically acceptable salt or prodrug thereof.

51. The kit of parts according to claim 47 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.